estriol has been researched along with Endometrial Neoplasms in 10 studies
hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone
chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.
Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "No one atypical endometrial hyperplasia and endometrial intraepithelial neoplasia case during the study period was found." | 3.11 | Genitourinary syndrome, local oestrogen therapy and endometrial pathology: a single-centre, randomised study. ( Kovachev, MS; Kovachev, SM, 2022) |
| " However, little is known about the risk of breast cancer and endometrial cancer after long-term use of different estrogen-progestin combinations." | 2.41 | [Hormone therapy in climacteric. Different effects of estrogen and gestagen on the risk of breast and endometrial cancer]. ( Magnusson, C; Weiderpass, E, 2001) |
| " In conclusion, 2ME, alone or in combination with TRAIL, may be an effective treatment for cancers of uterine origin with minimal toxicity to corresponding healthy female reproductive tissue." | 1.34 | The oestrogen metabolite 2-methoxyoestradiol alone or in combination with tumour necrosis factor-related apoptosis-inducing ligand mediates apoptosis in cancerous but not healthy cells of the human endometrium. ( Brañes, J; Brosens, JJ; Cuello, M; Kato, S; Lange, S; Owen, GI; Sadarangani, A; Villalón, M, 2007) |
| "Mortality from endometrial cancer was not related to the prescription of weak estrogens or an estrogen-progestin combination, but mortality was 40% higher in women prescribed more potent estrogens without a progestin." | 1.30 | Cause-specific mortality in women receiving hormone replacement therapy. ( Adami, HO; Hoover, R; Persson, I; Schairer, C, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Slomovitz, BM | 1 |
| Filiaci, VL | 1 |
| Walker, JL | 1 |
| Taub, MC | 1 |
| Finkelstein, KA | 1 |
| Moroney, JW | 1 |
| Fleury, AC | 1 |
| Muller, CY | 1 |
| Holman, LL | 1 |
| Copeland, LJ | 1 |
| Miller, DS | 1 |
| Coleman, RL | 1 |
| Kovachev, SM | 1 |
| Kovachev, MS | 1 |
| Davis, R | 1 |
| Batur, P | 1 |
| Thacker, HL | 1 |
| Stanosz, S | 1 |
| Mizunuma, H | 1 |
| Kato, S | 1 |
| Sadarangani, A | 1 |
| Lange, S | 1 |
| Villalón, M | 1 |
| Brañes, J | 1 |
| Brosens, JJ | 1 |
| Owen, GI | 1 |
| Cuello, M | 1 |
| Niwa, K | 1 |
| Murase, T | 1 |
| Furui, T | 1 |
| Morishita, S | 1 |
| Mori, H | 2 |
| Tanaka, T | 1 |
| Tamaya, T | 1 |
| Schairer, C | 1 |
| Adami, HO | 2 |
| Hoover, R | 1 |
| Persson, I | 2 |
| Weiderpass, E | 2 |
| Baron, JA | 1 |
| Magnusson, C | 2 |
| Lindgren, A | 1 |
| Bergström, R | 1 |
| Correia, N | 1 |
3 reviews available for estriol and Endometrial Neoplasms
| Article | Year |
|---|---|
Risks and effectiveness of compounded bioidentical hormone therapy: a case series.
Topics: Aged; Biosimilar Pharmaceuticals; Drug Compounding; Endometrial Neoplasms; Estradiol; Estriol; Estro | 2014 |
[Treatment of osteoporosis with estrogen].
Topics: Bone Density; Breast Neoplasms; Endometrial Neoplasms; Estriol; Estrogen Replacement Therapy; Estrog | 2004 |
[Hormone therapy in climacteric. Different effects of estrogen and gestagen on the risk of breast and endometrial cancer].
Topics: Aged; Breast Neoplasms; Case-Control Studies; Climacteric; Endometrial Neoplasms; Estriol; Estrogen | 2001 |
2 trials available for estriol and Endometrial Neoplasms
| Article | Year |
|---|---|
A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Endometrial Neoplasms; Estradiol; | 2022 |
Genitourinary syndrome, local oestrogen therapy and endometrial pathology: a single-centre, randomised study.
Topics: Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Estriol; Estrogen Replacement Therapy; | 2022 |
5 other studies available for estriol and Endometrial Neoplasms
| Article | Year |
|---|---|
An attempt at conservative treatment in selected cases of type I endometrial carcinoma (stage I a/G1) in young women.
Topics: Adult; Bromocriptine; Dilatation and Curettage; Endometrial Neoplasms; Endometrium; Estriol; Female; | 2009 |
The oestrogen metabolite 2-methoxyoestradiol alone or in combination with tumour necrosis factor-related apoptosis-inducing ligand mediates apoptosis in cancerous but not healthy cells of the human endometrium.
Topics: 17-Hydroxysteroid Dehydrogenases; Antineoplastic Agents; Apoptosis; Caspases; Cell Line; Cell Line, | 2007 |
Enhancing effects of estrogens on endometrial carcinogenesis initiated by N-methyl-N-nitrosourea in ICR mice.
Topics: Adenocarcinoma; Animals; Endometrial Hyperplasia; Endometrial Neoplasms; Estradiol; Estriol; Estrone | 1993 |
Cause-specific mortality in women receiving hormone replacement therapy.
Topics: Adult; Aged; Cause of Death; Cerebrovascular Disorders; Cohort Studies; Confidence Intervals; Drug T | 1997 |
Low-potency oestrogen and risk of endometrial cancer: a case-control study.
Topics: Administration, Intravaginal; Administration, Oral; Aged; Case-Control Studies; Endometrial Hyperpla | 1999 |